Navigation Links
Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
Date:8/26/2010

CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Sermo (http://www.sermo.com/client), the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS).  According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor.

The Sermo Report polled 60 physicians, many of who also participated in a discussion about the treatment. Acute coronary syndrome (ACS) incorporates a number of symptoms consistent with the probability that a patient is suffering from active Myocardial Infarction. Competitors to ticagrelor include Bristol-Myers Squibb Co. and Sanofi-Aventis', Plavix and Effient, sold by Eli Lilly & Company.

"Physicians on Sermo see ticagrelor as significantly impactful to clinicians," said Adam Sharp, Chief Medical Officer at Sermo. "However, cost and time in market could slow adoption. While more research on physician awareness still needs to be done, it's also interesting to note that 50% of docs did not know about the FDA approval before seeing it on Sermo."

Highlights from the report include:

  • Cost, time in market and generic Plavix were identified as three issues that could dissuade physicians from writing ticagrelor.
  • Reversibility and less post-operative bleeding were identified as possible advantages of this medication over Plavix.

Physicians shared their views of ticagrelor:

"While cost is certainly an issue we deal with all the time (can't wait until Plavix goes generic), there are some advantages with this medication – the biggest being the reversibility. I would be curious to see in the future how cardiac surgeons feel when this drug is in use – will they find that the drug really is reversible and that they find less post-operative bleeding. This would be a clear benefit over Plavix."

--Cardiologist, Sermo physician

"I would wait for a year or two to start prescribing it systematically. This time should be sufficient to elucidate the side-effect profile of the drug."

---Critical Care, Sermo physician

The full Sermo report includes key findings, MD demographics and post analysis.

Download the free report at http://www.sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about drugs, devices, treatments, and trends. Data for Sermo Reports are gathered through Sermo Posts, which allow physicians to participate in a poll and discussion about the topic.

About Sermo

Sermo is the largest online physician community, where over 115,000 practicing physicians discuss clinical cases and get advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit http://www.sermo.com/clients.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
2. NCPA: AARP Report Finds Brand Name Drug Prices Soar as Large Pharmacy Benefit Managers Reap Windfall Profits
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Kewaunee Scientific Reports Sales and Earnings for First Quarter
7. Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market
8. Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Transformational M&A achieved through NPS ... --> Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions ... for future growth with most robust pipeline in Shire ... future growth with most robust pipeline in Shire , ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... Exactus Pharmacy Solutions, a WellCare (NYSE: ... care for those suffering from long-term, life-threatening or ... Specialty Pharmacy Accreditation from URAC, an independent, nonprofit ... care quality through accreditation, education and measurement. ... URAC accreditation process demonstrates a commitment to quality ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 budget request ... shift more of the cost burden to military beneficiaries. , MOAA’s president, retired ... defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. ...
(Date:2/11/2016)... ... 2016 , ... In a new paper published in the ... Rod J. Rohrich, and colleagues, examine and underscore the importance of upper lateral ... when addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO Robert ... will focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities ... practices in data breaches for the Part D Star Rating improvement and Medication ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced ... , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking ... During his session, “ Coding for Care: Using Data Analytics for Risk Adjustment ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical ... in the heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, ... highest level of medical care in the convenience of their homes, offices or at ...
Breaking Medicine News(10 mins):